# Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

> **NCT00148395** · PHASE3 · COMPLETED · sponsor: **Aktion Bronchialkarzinom e.V.** · enrollment: 280 (—)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Navelbine
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Mitomycin
- **DRUG:** Ifosfamide

## Key facts

- **NCT ID:** NCT00148395
- **Lead sponsor:** Aktion Bronchialkarzinom e.V.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2008-04
- **Target enrollment:** 280 (—)
- **Last updated:** 2008-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148395, "Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00148395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*